A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial To Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy in Essential Hypertension Subjects Inadequately Controlled by D064 Monotherapy

A30_14HT2209

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy.

2022-09-28

2023-10-01

2023-10-01

Recruiting

Early phase I

108

Inclusion Criteria: 1. Subjects who are 19 years old or older. 2. Subjects who have voluntarily decided to participate in this clinical trial and signed ICF. Exclusion Criteria: 1. Subjects with a history of secondary hypertension or suspected secondary hypertension 2. Subjects who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period 3. Subjects with hypersensitivity or history of clinical trial drugs and similar drugs 4. Subjects who are required to administer a combination of prohibited drugs specified in this plan during the clinical trial participation period 5. Subjects with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening 6. Subjects who received other clinical trial drugs within 4 weeks of screening visit. 7. Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug 8. Subjects who are unable to participate in this clinical trial at the discretion of the investigator.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 108, 'type': 'ESTIMATED'}}

2022-11-28